PharmaPoint: Prostate Cancer ? Global Drug Forecast and Market Analysis to 2023
Single User License - $10995 Site User License - $21990 Corporate User License - $32985 Publication Date - Apr 2015 Pages - 264 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary • Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with earlystage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’s Provenge, Sanofi’s Jevtana, Johnson & Johnson’s Zytiga, Medivation/Astellas’ Xtandi, and Bayer’s Xofigo. During the forecast period from 2013–2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. Contact: debora@reportstack.com Reportstack Market Research
Scope • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical staging, symptoms, prognosis, quality of life, and disease management. • Annualized prostate cancer therapeutics market revenue from 2013–2023. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included. • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the prostate cancer therapeutics market. • Pipeline analysis: The prostate cancer pipeline is robust with many late-stage candidates set to launch in the forecast period. Comprehensive analysis of the nine most promising candidates in Phase III development are highlighted and profiled.
Contact: debora@reportstack.com Reportstack Market Research
Key Findings • The prostate cancer market, in the 9MM is forecasted to rapidly increase from $2.6bn in 2013 to $8.3bn in 2023, at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer. • The expects Medivation and Astellas’ Xtandi will become the market leader in prostate cancer. Xtandi is currently approved for pre- and post-chemotherapy metastatic castration-resistant prostate cancer (CRPC). Over the course of the forecast period, the data anticipates it will receive label extensions in nonmetastatic CRPC and hormone-sensitive prostate cancer, making it available to virtually all prostate cancer patients segments, with the exception of those with localized disease.
Contact: debora@reportstack.com Reportstack Market Research
Companies Mentioned Abbott Actavis Active Biotech Advantagene Amgen Astellas AstraZeneca Bavarian Nordic Bayer Bristol-Myers Squibb Daiichi-Sankyo Debiopharm Group Dendreon Ferring Pharmaceuticals GreenPeptide, etc Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research